PAS
CDTX

Point72 Asia (Singapore)’s Cidara Therapeutics CDTX Stock Holding History

Point72 Asia (Singapore)’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,552
Closed -$33.4K – 930
2025
Q1 		$33.4K Sell
1,552
-533
-26% -$11.8K 0.01% 630
2024
Q4 		$56K Buy
+2,085
New +$33.9K 0.01% 490

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asia (Singapore)'s CDTX Position: Q2 2025 in Review

Point72 Asia (Singapore) sold out of Cidara Therapeutics (CDTX) in Q2 2025, closing a stake of 1,552 shares — an estimated $33.4K sold.

Point72 Asia (Singapore) first reported a position in CDTX in Q4 2024 and held it in 2 quarters. The position peaked at $56K in Q4 2024. 109 funds tracked by Wall St. Rank hold CDTX as of Q2 2025.

  • Point72 Asia (Singapore) reported no remaining Cidara Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 1,552 Cidara Therapeutics shares in Q2 2025, an estimated $33.4K.
  • Point72 Asia (Singapore) first reported a position in Cidara Therapeutics in Q4 2024 and held it in 2 quarters.
  • Point72 Asia (Singapore)'s Cidara Therapeutics position peaked at $56K in Q4 2024.
  • 109 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2025, filed 14 Aug 2025.